The Efficacy and Safety of tDCS in Patients With Mild to Moderate Major Depressive Disorder

Ybrain

Status

Completed

Conditions

Depression

Treatments

Device: Mind STIM

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT04720040

YB_ST_SIT1902

Details and patient eligibility

About

This study evaluated the effectiveness and safety of improving depressive symptoms by applying tDCS for 6 weeks to patients with mild to moderate depression.

Full description

Patients received tDCS for 30 minutes with an intensity of 1.5 to 2 mA. tDCS was applied over the left (anode) and right (cathode) dorsolateral prefrontal cortex (DLPFC) 5~7 times a week and they were evaluated every 2weeks through questionnaires.

Enrollment

65 patients

Sex

All

Ages

19 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Has a diagnosis of a major depressive disorder as confirmed by the DSM-V and MINI (without psychotic features)
Patients with a K-BDI-II score of 14 or more and 28 or less
In the case of patients who have previously administered antidepressants, antipsychotics, and anticonvulsants for at least 1 week, Patients with sufficient drug treatment periods of at least 5 times the drug half-life.

Exclusion criteria

Patients diagnosed with Axis I disorders other than major depressive disorder
Patients diagnosed with other depressive disorders besides major depressive disorder
Patients who have attempted suicide within 6 months of screening
Patients who are considered to have problems with EEG and DC stimulation electrode attachment due to scalp deformity, inflammatory reaction, or other dermatological problems
Patients judged to have other reasons for prohibition of use of tDCS medical devices
Patients currently taking antidepressants